Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Immunotherapy-Related Myocarditis

      June 11, 2019
      By Javid J. Moslehi, MD
      Video
      Conferences|ONS Annual Congress

      Nurses should be aware of patients who are at risk for immunotherapy-related myocarditis.

      Researchers have noticed a new clinical syndrome for patients treated with immune checkpoint inhibitors: myocarditis, explained Javid J. Moslehi, MD, director of cardio-oncology at the Vanderbilt University Medical Center.

      The syndrome involves inflammation of the myocardium (heart muscle), and has mostly been seen in patients who are on combination drug regimens. The most aggressive cases of myocarditis usually occur after the first or second dose of immunotherapy, making this a crucial time for oncology nurses to monitor patients who may be at risk.

      TRANSCRIPTION

      We've been very interested, as these syndromes the immune checkpoint inhibitor-associated myocarditis is a new clinical syndrome. Our first job has been to better characterize what this syndrome really consists of. We have shown by pathology that it includes inflammation in the heart itself, in the myocardium, in the classic definition of myocarditis. These are mostly T cells and macrophages.

      We've described better which cancer syndromes and with which drugs they go with. It seems like if you combine therapies, you have a much higher risk of having myocarditis. We don't see a signal with one drug, so it all seems to be doing this. As best as we can tell, this is a class effect. In addition, most of the fulminant, very aggressive myocarditis cases that come about occur after the first or second dose. That's really important to note, and that provides some guidelines with how we may screen patients or do surveillance for patients who are at high risk.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Photo of a man wearing a suit in front of an Oncology Nursing News backdrop
      Photo of a woman with shoulder-length brown hair with a maroon shirt and black blazer
      Related Content

      Illustration of clinicians investigating a large illustrated lung

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Jax DiEugenio
      September 11th 2025
      Article

      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      September 11th 2025
      Podcast

      Image of blood cancer cells

      Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression

      Russ Conroy
      September 11th 2025
      Article

      The Vitals

      Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

      Lindsay Fischer
      September 11th 2025
      Podcast

      Image of bone marrow with cancer cells

      Venetoclax Combo Did Not Increase OS in Intermediate/High-Risk MDS

      Ariana Pelosci
      September 11th 2025
      Article

      Photo of a woman with blond hair in front of a greenery background

      Opinion: Nursing Considerations for Emerging CLDN6-Targeted Therapies

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      September 11th 2025
      Article
      Related Content

      Illustration of clinicians investigating a large illustrated lung

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Jax DiEugenio
      September 11th 2025
      Article

      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      September 11th 2025
      Podcast

      Image of blood cancer cells

      Subcutaneous Daratumumab Reduces Smoldering Myeloma Progression

      Russ Conroy
      September 11th 2025
      Article

      The Vitals

      Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

      Lindsay Fischer
      September 11th 2025
      Podcast

      Image of bone marrow with cancer cells

      Venetoclax Combo Did Not Increase OS in Intermediate/High-Risk MDS

      Ariana Pelosci
      September 11th 2025
      Article

      Photo of a woman with blond hair in front of a greenery background

      Opinion: Nursing Considerations for Emerging CLDN6-Targeted Therapies

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      September 11th 2025
      Article

      Latest Conference Coverage

      Safety Management With Amivantamab Plus Lazertinib in NSCLC

      Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

      Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

      Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      259 Prospect Plains Rd, Bldg H,
      Monroe, NJ 08831

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.